[Is GHB use in Switzerland on the rise?].
Pfeifer
H R
HR
Forschungsgruppe Substanzstörungen, Psychiatrische Universitätsklinik Zürich. hans-rudolf.pfeifer@puk.zh.ch
Stohler
R
R
D015107:4-Butyrolactone / Q000008:administration & dosage / Q000494:pharmacology; D000759:Adjuvants, Anesthesia / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000284:Administration, Oral; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D006801:Humans; D013287:Illicit Drugs; D012978:Sodium Oxybate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000506:poisoning / Q000627:therapeutic use; D012997:Solvents / Q000008:administration & dosage; D019966:Substance-Related Disorders; D013557:Switzerland; D013997:Time Factors
D000759:Adjuvants, Anesthesia; D018686:Anesthetics, Intravenous; D013287:Illicit Drugs; D012997:Solvents; D012978:Sodium Oxybate; D015107:4-Butyrolactone
Zunehmender Konsum von GHB in der Schweiz?